Abstract：Objective To explore the clinical effect of Montelukast in the treatment of children with cough variant asthma.Methods A total of 86 children with cough variant asthma admitted to our hospital from February 2016 to February 2017 were enrolled in the observation group(43 cases)and the control group(43 cases)according to the random number table method.The control group was treated with conventional inhaled Budesonide Aerosol,and the observation group was treated with Montelukast.The clinical treatment effect,lung function index level,cough remission time,cough disappearance time,daily asthma attack number,night asthma attack frequency,short-acting bronchodilator use times,adverse reactions and recurrence were compared between the two groups.Results The total effective rate of the observation group was 95.35%,which was significantly higher than 79.07%of the control group,the difference was statistically significant(P<0.05).After treatment,the number of asthma attacks on the day and night of the observation group were (4.42±0.98)times/month,(3.38±1.25)times/month,and the number of short-acting bronchodilators used was(2.45±1.20)d/month,significantly less than(5.76±1.24)times/month,(4.17±0.96)times/month,(4.18±1.23)d/month in the control group,the differences were statistically significant(P<0.05).The forced expiratory volume(FEV1)of the observation group was(3.04±0.40)L,the forced vital capacity(FVC)was(3.89±0.56)L,and the FEV1/FVC was(75.93±6.14)%,which were significantly higher than(2.81±0.32)L,(3.34±0.41)L,(68.76±5.34)%in the control group,the differences were statistically significant(P<0.05).The cough relief time of the observation group was(4.01±1.24)d,and the cough disappearance time was(6.59±1.62)d,which were significantly shorter than(5.87±1.36)d,(7.94±1.58)d in the control group,the differences were statistically significant(P<0.05).The disease recurrence rate of the observation group was 9.30%after 6 months,which was significantly lower than that of the control group(30.23%),the difference was statistically significant(P<0.05).There was no significant difference in the overall incidence of adverse reactions between the two groups (P>0.05).Conclusion The use of Montelukast in the treatment of children with cough variant asthma can effectively improve the clinical symptoms of children,promote the normal operation of lung function,shorten the treatment time of patients,and reduce the recurrence rate of the disease.
京公网安备 11010502046607号